Tag: Eli Lilly and Co

Advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, according to FDA

Eli Lilly, a pharmaceutical company headquartered in Indianapolis, Indiana, received positive news when a panel of independent advisors to the Food and Drug Administration (FDA) recommended the approval of their experimental Alzheimer’s drug, donanemab. The recommendation paves the way for the treatment to receive full approval in the U.S. later this year, expanding treatment options […]

Eli Lilly makes investment to boost supply of Mounjaro and Zepbound

Eli Lilly, a pharmaceutical giant, is making a massive investment in a manufacturing plant in Lebanon, Indiana, to address the high demand for its weight loss drug Zepbound, diabetes treatment Mounjaro, and other medicines. The company is putting in an additional $5.3 billion, bringing its total investment at the site to $9 billion, marking its […]

Digital health companies are introducing initiatives focused on GLP-1s

In recent years, the demand for GLP-1s, a class of obesity treatments, has surged, leading to the development of various programs and services to support users. Companies like Ro, Calibrate, WeightWatchers, Hims & Hers, and others have capitalized on this trend by offering comprehensive programs for patients on GLP-1s. These programs provide access to medications […]

A potential $25 billion market opportunity for the emerging cancer treatment

Big pharma is making big investments in the field of targeted radiopharmaceutical therapy, which delivers radiation directly into tumors by attaching radioactive particles to targeting molecules. This emerging class of cancer treatments has caught the attention of Wall Street, with RBC Capital Markets estimating a $25 billion market opportunity. Novartis, a market leader in targeted […]

Early trial results show promising outcomes for Roche’s new weight loss drug

Roche’s Promising Weight Loss Drug Shows Positive Results in Early-Stage Trial Roche, a multinational healthcare company, has recently announced promising results from an early-stage trial of its experimental weight loss drug, CT-388. The drug, which is still in development, has shown significant potential in helping patients with obesity achieve substantial weight loss. The Swiss company’s […]

Survey finds that 1 in 8 adults have tried GLP-1 medications such as Ozempic

The use of GLP-1 drugs for weight loss and diabetes management is on the rise, with around 1 in 8 adults in the U.S. having used these medications at some point. A recent survey from KFF revealed that roughly half of those adults, or about 6% of the U.S. population, are currently using GLP-1 drugs […]

Back To Top